Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) reported Q2 2017 earnings this Morning, coming in at $1.56 per share, beating Wall Street’s estimates of $1.25 per Share. Revenue for the quarter came in at $912.00 million beating analyst estimates of $846.15 million
Analyst Coverage For Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
These are 6 Hold Ratings, 16 Buy Ratings, 1 Strong Buy Rating .
The current consensus rating for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is Buy (Score: 2.78) with a consensus target price of $157.86 , a potential (20.44% upside)Recent Insider Trading for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
- On 6/15/2017 Bros. Advisors Lp Baker, Director, bought 660,779 with an average share price of $117.33 per share and the total transaction amounting to $77,529,200.07.
- On 6/14/2017 Bros. Advisors Lp Baker, Director, bought 1,348,955 with an average share price of $116.32 per share and the total transaction amounting to $156,910,445.60.
- On 6/14/2017 Ludwig Hantson, CEO, bought 10,000 with an average share price of $116.72 per share and the total transaction amounting to $1,167,200.00.
- On 3/1/2017 Clare Carmichael, EVP, sold 2,179 with an average share price of $131.66 per share and the total transaction amounting to $286,887.14.
- On 3/1/2017 Heidi L Wagner, SVP, sold 994 with an average share price of $131.65 per share and the total transaction amounting to $130,860.10.
- On 3/1/2017 Leonard Bell, Director, sold 3,978 with an average share price of $131.96 per share and the total transaction amounting to $524,936.88.
Recent Trading for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Shares of Alexion Pharmaceuticals, Inc. closed the previous trading session at 135.12 up +4.05 3.09% with 2,055,575 shares trading hands.